Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 11, 2018 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Granted Japanese Patent for CLR 131

FLORHAM PARK, N.J., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...
December 04, 2018 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma

FLORHAM PARK, N.J., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
November 13, 2018 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update

FLORHAM PARK, N.J., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (“Cellectar” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery,...
November 12, 2018 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies

Clinical Trials to Advance Across Multiple Hematology Programs FLORHAM PARK, N.J., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical...
October 02, 2018 08:00 ET | Source: Cellectar Biosciences, Inc.

Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma

MADISON, Wis., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
September 27, 2018 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare Conference

MADISON, Wis., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
September 25, 2018 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma

MADISON, Wis., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
September 24, 2018 08:00 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Provides an Update on the FDA Import Alert

MADISON, Wis., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
September 17, 2018 08:30 ET | Source: Cellectar Biosciences, Inc.

FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma

MADISON, Wis., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
August 29, 2018 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

MADISON, Wis., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...